HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU CBD Market Under Threat With Narcotic Classification Favored

Executive Summary

Leaning towards classifying CBD as a narcotic, the European Commission could dash hopes of a regulated EU market for dietary supplements containing the cannabinoid. 

You may also be interested in...



CBD Supplements, Teas And Flowers Up To 0.3% THC Allowed In France, For Now

France's Ministry of Solidarity and Health published a decree allowing the commercial sale of cannabis sativa extracts with a maximum THC content up to 0.3%, but banning the sale of raw cannabis flowers and leaves to consumers in all their forms, thus elimating a booming CBD market for tea, for example. The ban, however, has been halted by France's highest administrative court on the basis that it is disproportionate. While the Conseil d’Etat makes its final decision, French bricks-and-mortar and online CBD retailers can continue selling low-THC cannabis flowers and leaves.

European Commission Decides CBD Is Not A Drug Opening Up Novel Food Pathway

The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.

European Commission Evaluating CBD Court Ruling Ahead Of Crucial UN Vote

With the European Commission "carefully assessing" the judgment of Europe's highest court that CBD is not a narcotic, HBW Insight speaks to an expert in cannabis law about what is likely to happen next.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS150264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel